This issue includes six articles that present logic, methods, and models for causal analyses of observational data, in particular those based on propensity score (PS) methods. The articles include a general introduction to propensity score analysis (PSA), uses of PSA in mediation studies, issues involved in choosing covariates, challenges that often arise in PSA applications, hierarchical data issues and models, and an application in an educational testing context. In this editorial I briefly summarize each article and make a few recommendations that relate to future applications in this field: the first pertains to how propensity score (PS) work could profit by connecting it with stronger forms of randomized experiments, not just simple randomization; the second to how and why graphical methods could be used to greater advantage in PSA studies; then why it might be helpful to reconsider the meaning of the term "treatments" in observational studies and why conventional usage might be modified; and finally, to the distinction between retrospective and prospective approaches to observational study design, noting the advantages, when feasible, of the latter approach.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/00273171.2011.576618 | DOI Listing |
Spine (Phila Pa 1976)
January 2025
The Permanente Medical Group, Oakland, CA.
Study Design: A retrospective cohort study.
Objective: To determine if there is a difference in reoperations for adjacent segment disease (operative ASD) and nonunion (operative nonunion) in lumbar fusions that stop at T10/T11/T12 versus L1.
Summary Of Background Data: Current lumbar spine surgery is based on the belief that ASD occurs if fusions are stopped at L1 although there is varying evidence to support this assumption.
Chron Respir Dis
January 2025
Brunel University London, College of Health Medicine and Life Sciences, London, UK.
Pulmonary rehabilitation (PR) services are increasingly using alternative programme delivery modes, for example telerehabilitation strategies including videoconferencing, to improve patient choice and accessibility. Although telerehabilitation results in improvements in core outcomes, the effect on knowledge attainment is not known. To observe the real-world responses of patients choosing to undergo videoconference PR to a matched control group choosing to undergo in-person PR, in terms of knowledge attainment.
View Article and Find Full Text PDFHead Neck
January 2025
Department of Radiation Oncology, Eye & ENT Hospital, Fudan University, Shanghai, China.
Objectives: We aimed to compare the outcomes of patients with T1-T2N0M0 glottic squamous cell carcinoma who underwent either partial laryngectomy (PL) or radiotherapy (RT).
Methods: A retrospective analysis of 562 patients treated with RT (n = 151) or PL (n = 411) was conducted. The Kaplan-Meier method was used to estimate outcomes.
Infect Drug Resist
January 2025
Department of Respiratory and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People's Republic of China.
Objective: To evaluate the diagnostic performance and clinical impact of targeted next-generation sequencing (tNGS) in patients with suspected lower respiratory tract infections.
Methods: Following propensity score matching, we compared the diagnostic performances of tNGS and metagenomic next-generation sequencing (mNGS). Furthermore, the diagnostic performance of tNGS was compared with that of culture, and its clinical impact was assessed.
Front Pharmacol
January 2025
Department of Oncology, Binzhou Medical University Hospital, Binzhou, Shandong, China.
Purpose: The present work focused on assessing whether hepatic arterial infusion chemotherapy (HAIC) combined with lenvatinib and tislelizumab was safe and effective on advanced hepatocellular carcinoma (HCC) showing high tumor burden.
Methods: In the present multicenter retrospective study, treatment-naive advanced HCC patients (BCLC stage C) showing high tumor burden (maximum diameter of intrahepatic lesion beyond 7 cm) treated with lenvatinib and tislelizumab with or without HAIC were reviewed for eligibility from June 2020 to June 2023. Baseline differences between groups were mitigated by propensity score matching (PSM).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!